scholarly journals Immune Protective Efficacy of China’s Traditional Inactivated and Attenuated Vaccines against the Prevalent Strains of Pasteurella multocida in Mice

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1155
Author(s):  
Li-Jun Guan ◽  
Ji-Jian Song ◽  
Yun Xue ◽  
Xia Ai ◽  
Zhi-Jun Liu ◽  
...  
Keyword(s):  
Mouse Model ◽  
Protective Effect ◽  
Aluminum Hydroxide ◽  
Pasteurella Multocida ◽  
Protective Efficacy ◽  
Cross Protection ◽  
Immune Protection ◽  
Capsular Type ◽  
Protection Effect ◽  
Antibody Titers

Capsular type A and D strains of Pasteurella multocida are the main epidemic serogroups in pigs in China. In this study, we preliminarily evaluated the immune protective efficacy of the two traditional vaccines, an inactivated C44-1 aluminum-hydroxide-gel-adjuvanted (Alh–C44-1) vaccine and a live EO630 vaccine, against currently circulating strains of P. multocida in a mouse model. Mice immunized twice with conventional vaccines generated higher antibody titers, and significantly higher levels of IgG were observed in the mice inoculated with the inactivated Alh–C44-1 vaccine on day 35 (p < 0.05) than those with the live EO630 vaccine. The mice immune protection test showed that the vaccination groups had a 57% or 71% protection effect against the serogroup B strain, but had no protective effect against epidemic strains. In conclusion, our study found that the widely used traditional P. multocida vaccines in China provide good protection against homologous strains, but could not provide cross-protection against heterologous strains in a mouse model.

scholarly journals A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model

2021 ◽  
Vol 12 ◽  
Author(s):  
Minjin Kim ◽  
Yucheol Cheong ◽  
Jinhee Lee ◽  
Jongkwan Lim ◽  
Sanguine Byun ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Mouse Model ◽  
Neutralizing Antibodies ◽  
Influenza A ◽  
Protective Efficacy ◽  
Influenza Viruses ◽  
Cross Protection ◽  
Infection Model ◽  
Wild Type ◽  
Group 1

Influenza virus infections can cause a broad range of symptoms, form mild respiratory problems to severe and fatal complications. While influenza virus poses a global health threat, the frequent antigenic change often significantly compromises the protective efficacy of seasonal vaccines, further increasing the vulnerability to viral infection. Therefore, it is in great need to employ strategies for the development of universal influenza vaccines (UIVs) which can elicit broad protection against diverse influenza viruses. Using a mouse infection model, we examined the breadth of protection of the caspase-triggered live attenuated influenza vaccine (ctLAIV), which was self-attenuated by the host caspase-dependent cleavage of internal viral proteins. A single vaccination in mice induced a broad reactive antibody response against four different influenza viruses, H1 and rH5 (HA group 1) and H3 and rH7 subtypes (HA group 2). Notably, despite the lack of detectable neutralizing antibodies, the vaccination provided heterosubtypic protection against the lethal challenge with the viruses. Sterile protection was confirmed by the complete absence of viral titers in the lungs and nasal turbinates after the challenge. Antibody-dependent cellular cytotoxicity (ADCC) activities of non-neutralizing antibodies contributed to cross-protection. The cross-protection remained robust even after in vivo depletion of T cells or NK cells, reflecting the strength and breadth of the antibody-dependent effector function. The robust mucosal secretion of sIgA reflects an additional level of cross-protection. Our data show that the host-restricted designer vaccine serves an option for developing a UIV, providing pan-influenza A protection against both group 1 and 2 influenza viruses. The present results of potency and breadth of protection from wild type and reassortant viruses addressed in the mouse model by single immunization merits further confirmation and validation, preferably in clinically relevant ferret models with wild type challenges.

scholarly journals Protective efficacy of calcium phosphate nanoparticle adsorbed bivalent subunit vaccine of Pasteurella multocida against homologous challenge in mice

2020 ◽  
Author(s):  
Songyukta Shyam ◽  
Shantanu Tamuly ◽  
Probodh Borah ◽  
Rajeev Kumar Sharma
Keyword(s):  
Calcium Phosphate ◽  
Subunit Vaccine ◽  
Pasteurella Multocida ◽  
Protective Efficacy ◽  
Economic Loss ◽  
Capsular Type ◽  
Significant Protection ◽  
Type B ◽  
Serotype A ◽  
Calcium Phosphate Nanoparticle

ABSTRACTSwine pasteurellosis, caused by Pasteurella multocida capsular types A and D, causes heavy economic loss to the pig farmers. The vaccine presently used is abacterin of Pasteurella multocida capsular type B that is proven to be effective against bovine pasteurellosis. However, its efficacy against swine pasteurellosis is questionable. The present study was carried out to evaluate the efficacy of calcium phosphate nanoparticle adjuvanted bivalent subunit vaccine prepared from Pasteurella multocida capsular types A and D along with a monovalent subunit vaccine prepared from Pasteurella multocida capsular type B in mice. The Alum precipitated bacterin vaccine was used as the control. The bivalent subunit vaccine comprising the immune components of both the capsular types showed significantly higher IgG response than either of the other two vaccines. Both the calcium phosphate nanoparticle adjuvanted vaccines could elicit 100% protection in mice against homologous challenges but the aluminum hydroxide adjuvanted bacterin vaccine could not elicit significant protection. Based on this preliminary work, it was concluded that the bivalent subunit vaccine would be a better option for immunization of swine against swine pasteurellosis.IMPORTANCE OF THE WORKThe swine pasteurellosis is an important economic disease affecting the pig population in the North-eastern part of India that contributes the major pig population. The disease is caused by Serotype A and D of Pasteurella multocida. At present the inactivated vaccine is used that is actually developed against P52 strain of serotype B:2 of Pasteurella multocida, which is mainly involved in haemorrhagic septicaemia (or bovine pasteurellosis) that affects the cattle, buffaloe, sheep and goat. As a result, the present vaccine does not give sufficient protection in pigs but gives significant protection in cattle, buffaloe, sheep and goat. Hence, there is a need of development of vaccine that can address specifically swine pasteurellosis by targeting serotype A and D of Pasteurella multocida.

scholarly journals Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model

2014 ◽  
Vol 21 (5) ◽  
pp. 722-731 ◽  
Author(s):  
Irina Isakova-Sivak ◽  
Li-Mei Chen ◽  
Melissa Bourgeois ◽  
Yumiko Matsuoka ◽  
J. Theo M. Voeten ◽  
...  
Keyword(s):  
Mouse Model ◽  
Reverse Genetics ◽  
Protective Efficacy ◽  
Influenza Pandemic ◽  
Lethal Dose ◽  
Challenge Inoculation ◽  
Cold Adapted ◽  
Antibody Titers ◽  
Inactivated Vaccines ◽  
Clade 1

ABSTRACTLive attenuated influenza vaccines (LAIV) offer significant advantages over subunit or split inactivated vaccines to mitigate an eventual influenza pandemic, including simpler manufacturing processes and more cross-protective immune responses. Using an established reverse genetics (rg) system for wild-type (wt) A/Leningrad/134/1957 and cold-adapted (ca) A/Leningrad/134/17/1957 (Len17) master donor virus (MDV), we produced and characterized three rg H5N1 reassortant viruses carrying modified HA and intact NA genes from either A/Vietnam/1203/2004 (H5N1, VN1203, clade 1) or A/Egypt/321/2007 (H5N1, EG321, clade 2) virus. A mouse model of infection was used to determine the infectivity and tissue tropism of the parentalwtviruses compared to thecamaster donor viruses as well as the H5N1 reassortants. Allcaviruses showed reduced replication in lungs and enhanced replication in nasal epithelium. In addition, the H5N1 HA and NA enhanced replication in lungs unless it was restricted by the internal genes of thecaMDV. Mice inoculated twice 4 weeks apart with the H5N1 reassortant LAIV candidate viruses developed serum hemagglutination inhibition HI and IgA antibody titers to the homologous and heterologous viruses consistent with protective immunity. These animals remained healthy after challenge inoculation with a lethal dose with homologous or heterologouswtH5N1 highly pathogenic avian influenza (HPAI) viruses. The profiles of viral replication in respiratory tissues and the immunogenicity and protective efficacy characteristics of the twocaH5N1 candidate LAIV viruses warrant further development into a vaccine for human use.

Immunogenicity and Protective Efficacy of Iron-inactivated Pasteurella multocida A:1 Vaccine against Fowl Cholera in Backyard Chicken

2021 ◽  
Author(s):  
M. Abhilash ◽  
T.R. Kannaki ◽  
E. Priyanka ◽  
Santosh Haunshi
Keyword(s):  
Pasteurella Multocida ◽  
Protective Efficacy ◽  
Economic Loss ◽  
Bacterial Disease ◽  
Oil Emulsion ◽  
Fowl Cholera ◽  
Antibody Titers ◽  
Mortality Percentage ◽  
Backyard Chicken ◽  
Significant Economic Loss

Background: Fowl cholera is a highly fatal, contagious bacterial disease that incurs significant economic loss in commercial as well as back-yard poultry. Vaccination is the most effective way in controlling this disease. In this study, we prepared and evaluated the immunogenicity of iron- inactivated Pasteurella multocida A:1 vaccine and its protective efficacy against fowl cholera experimental infection in backyard chicken.Methods: Scaled up Pasteurella multocida A:1 culture with 5 X 108 CFU/ml equivalent to 2.5 mg of antigen per dose was used for preparation of experimental vaccines. Formalin inactivated and mixed with APS adjuvant (FIA), formalin inactivated-Freund adjuvant (FIF), Iron inactivated and adjuvanted with iron (III), Iron inactivated from iron supplemented media and adjuvanted with iron (ISII) and commercial oil emulsion vaccine (CV) were used in the study. A total of 120 Vanaraja birds (n=20/group) of 2 weeks age were immunized with these vaccine and booster were given at 3rd and 6th week with respective vaccine. Specific antibody titers were assessed by iELISA in the serum at weekly intervals. The birds were challenged (n=6 /group) with 5x104 CFU/ml of virulent isolate by intraperitoneal route and morbidity, mortality percentage were observed.Result: Protective antibody titers were induced by iron inactivated vaccine from 4th week of immunization and upon booster doses it induced significantly higher (P less than 0.05) antibody response. The iron inactivated experimental vaccine gave equivalent protection as that of commercial vaccine upon challenge infection.

The Protective Efficacy of Ethanolic Leaves Extract of Citronella Gras (Cymbopogon nardus) on Glucose Metabolism Alteration Induced By Mercury in Rats

2017 ◽  
Vol 9 (03) ◽  
Author(s):  
Fransisca Diana Alexandra ◽  
Dian Mutiasari ◽  
Trilianty Lestarisa ◽  
Eko Suhartono
Keyword(s):  
Glucose Metabolism ◽  
Protective Effect ◽  
Plant Extract ◽  
Protective Efficacy ◽  
Liver Weight ◽  
Liver Glycogen ◽  
Liver Cells ◽  
Glycogen Level ◽  
Group I ◽  
Citronella Grass

The present study was undertaken to investigate the protective effect of ethanolic citronella grass (C. nardus) leaves extract against mercury (Hg) induced glucose metabolism alteration in rats. Four groups of rats were selected, with 6 rats for each group. Animals of group I was received a 1 ppm of Hg only. Animals of groups II, III, and IV received a combination of 1 ppm Hg and plant extract in different dose (1650, 2520, and 3360 mg/ml). The experiment lasted for 4 weeks. The various parameters studied included liver weight, liver glucose, glycogen, and malondialdehyde (MDA) level in all groups after treatment. The results of this present studies showed that the Hg-induced glucose metabolism alteration in rats which can be seen from the increase of liver glucose and the decreasing of liver glycogen levels. The results also showed that the Hginduced glucose metabolism alteration through its activities in the trigger the liver cells damage which can be seen from the decreasing of liver weight and the increase of liver MDA level. The ethanolic of C. nardus leaves extract shows a protective effect to maintain all parameters into a better a condition which can be seen from the significant increase in liver weight and liver glycogen level, and the significant decrease in liver glucose and MDA levels. The present study indicated that the ethanolic C. nardus leaves extract showed a potential protective effect on glucose metabolism alteration induced by Hg

scholarly journals Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 142
Author(s):  
Yulong Wang ◽  
Nan Jiang ◽  
Linjin Fan ◽  
Li Gao ◽  
Kai Li ◽  
...  
Keyword(s):  
Disease Virus ◽  
Infectious Bursal Disease Virus ◽  
Protective Efficacy ◽  
Expression System ◽  
Size Exclusion ◽  
Candidate Vaccine ◽  
Infectious Bursal Disease ◽  
Immune Protection ◽  
Bursal Disease ◽  
Novel Variant

Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.

scholarly journals Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1347
Author(s):  
Claudia Maria Trombetta ◽  
Serena Marchi ◽  
Simonetta Viviani ◽  
Alessandro Manenti ◽  
Linda Benincasa ◽  
...  
Keyword(s):  
Natural Infection ◽  
Neutralizing Antibody ◽  
Original Strain ◽  
Immune Protection ◽  
Serum Samples ◽  
Symptomatic Infection ◽  
Neutralizing Activity ◽  
The United Kingdom ◽  
Antibody Titers ◽  
Pandemic Wave

The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (≥2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.

scholarly journals Immunogenicity and protective efficacy of enterotoxigenic Escherichia coli (ETEC) total RNA against ETEC challenge in a mouse model

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Mandi Liu ◽  
Yue Zhang ◽  
Di Zhang ◽  
Yun Bai ◽  
Guomei Liu ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Mouse Model ◽  
Immune Responses ◽  
Protective Efficacy ◽  
Enterotoxigenic Escherichia Coli ◽  
Economic Losses ◽  
Th2 Response ◽  
Total Rna ◽  
Etec Infection

AbstractEnterotoxigenic Escherichia coli (ETEC), an essential cause of post-weaning diarrhea (PWD) in piglets, leads to significant economic losses to the pig industry. The present study aims to identify the role of ETEC total RNA in eliciting immune responses to protect animals against ETEC infection. The results showed that the total RNA isolated from pig-derived ETEC K88ac strain effectively stimulated the IL-1β secretion of porcine intestinal epithelial cells (IPEC-J2). The mouse model immunized with ETEC total RNA via intramuscular injection (IM) or oral route (OR) was used to evaluate the protective efficiency of the ETEC total RNA. The results suggested that 70 μg ETEC total RNA administered by either route significantly promoted the production of the serum IL-1β and K88ac specific immunoglobulins (IgG, IgM, and IgA). Besides, the ETEC RNA administration augmented strong mucosal immunity by elevating K88ac specific IgA level in the intestinal fluid. Intramuscularly administered RNA induced a Th1/Th2 shift toward a Th2 response, while the orally administered RNA did not. The ETEC total RNA efficiently protected the animals against the ETEC challenge either by itself or as an adjuvant. The histology characterization of the small intestines also suggested the ETEC RNA administration protected the small intestinal structure against the ETEC infection. Particularly of note was that the immunity level and protective efficacy caused by ETEC RNA were dose-dependent. These findings will help understand the role of bacterial RNA in eliciting immune responses, and benefit the development of RNA-based vaccines or adjuvants.

Sign in / Sign up

Export Citation Format

Share Document